Published in Clin Genitourin Cancer on May 14, 2011
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 8.73
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet (2001) 2.85
Carcinoma of the prostate. N Engl J Med (1991) 2.47
Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience. Cancer (2003) 2.46
Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer (2007) 1.56
Disseminated intravascular coagulation in carcinoma of prostate: role of estrogen therapy. Urology (1983) 1.25
Presentation, treatment, and outcomes of dural metastases in men with metastatic castrate-resistant prostate cancer: a case series. J Palliat Med (2010) 1.18
Glucocorticoid receptor signaling and prostate cancer. Cancer Lett (2011) 1.13
Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst (1996) 1.11
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol (2005) 1.03
Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer (1980) 1.03
The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer. J Urol (1987) 0.92
Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol (2001) 0.84
The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer (2009) 0.84
Prostate cancer detection is also relevant in low prostate specific antigen ranges. Eur Urol (2004) 0.84
Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml. J Urol (2009) 0.83
Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study. Cancer (1992) 0.83
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer (2003) 0.83
Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study. Clin Transl Oncol (2009) 0.83
Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer. Am J Ther (2012) 0.82
Chronic intravascular coagulation. Clinical spectrum and diagnostic criteria, with special emphasis on metabolism, distribution and localization of I 131 -fibrinogen. Acta Med Scand Suppl (1971) 0.77
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am (2007) 1.75
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 1.67
Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer (2007) 1.56
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer (2007) 1.49
Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol (2007) 1.49
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A (2011) 1.09
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol (2002) 1.06
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer (2003) 1.05
Biology and clinical management of prostate cancer bone metastasis. Front Biosci (2007) 1.04
Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol (2004) 1.03
Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res (2007) 1.00
The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev (2006) 0.99
Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol (2009) 0.97
The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients. J Palliat Med (2011) 0.94
Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer (2006) 0.90
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res (2008) 0.87
Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer (2006) 0.86
Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience. Urol Oncol (2010) 0.84
Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases. Hum Pathol (2010) 0.83
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer (2003) 0.83
Stem cell origin of testicular seminoma. Clin Genitourin Cancer (2013) 0.81
Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urol Oncol (2006) 0.80
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer (2006) 0.80
Recurrent seminomas: clinical features and biologic implications. Urol Oncol (2010) 0.79
Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol (2011) 0.79
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol (2002) 0.79
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer (2003) 0.78
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer (2011) 0.77
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer (2014) 0.77
Targeting prostate cancer bone metastases. Cancer (2003) 0.77
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2003) 0.75
Cixutumumab-associated pancolitis in a patient with prostate cancer. Clin Genitourin Cancer (2012) 0.75
Radium-223: Optimizing Treatment and Research of Osteoblastic Bone Metastasis. Oncology (Williston Park) (2015) 0.75
Re: Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can J Urol (2012) 0.75
Variant prostate carcinoma and elevated serum CA-125. Can J Urol (2014) 0.75
Radiopharmaceuticals: present and future. J Support Oncol (2011) 0.75
Multisystem crisis in a patient with presumptive renal cell carcinoma. Clin Genitourin Cancer (2008) 0.75
Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol (2007) 0.75
Clinically atypical seminomas with yolk sac tumor features. Can J Urol (2013) 0.75
Recent developments in the management of germ cell tumors. Curr Opin Oncol (2017) 0.75
Multilocular cystadenoma and cystadenocarcinoma of the prostate. Urol Oncol (2007) 0.75
Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology (2007) 0.75